Bruker (NASDAQ:BRKR) Given New $65.00 Price Target at Barclays

Bruker (NASDAQ:BRKR) had its price objective trimmed by Barclays from $69.00 to $65.00 in a research report released on Monday morning,Benzinga reports. The firm currently has an overweight rating on the medical research company’s stock.

Other equities analysts have also issued research reports about the stock. UBS Group initiated coverage on shares of Bruker in a report on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 price target on the stock. The Goldman Sachs Group upgraded Bruker from a “sell” rating to a “neutral” rating and set a $60.00 target price on the stock in a report on Thursday, December 5th. TD Cowen dropped their price target on Bruker from $72.00 to $70.00 and set a “hold” rating for the company in a research note on Wednesday, November 6th. Guggenheim reaffirmed a “buy” rating on shares of Bruker in a research note on Friday, January 17th. Finally, Bank of America increased their target price on shares of Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Six investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $74.09.

Bruker Stock Performance

NASDAQ:BRKR opened at $51.13 on Monday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. The firm has a market cap of $7.75 billion, a PE ratio of 24.58, a P/E/G ratio of 3.81 and a beta of 1.16. The firm has a 50 day simple moving average of $58.18 and a 200-day simple moving average of $60.95. Bruker has a 1-year low of $48.07 and a 1-year high of $94.86.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Monday, December 2nd were given a $0.05 dividend. The ex-dividend date was Monday, December 2nd. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.39%. Bruker’s payout ratio is currently 9.62%.

Insider Buying and Selling

In related news, CEO Frank H. Laukien bought 100,000 shares of the business’s stock in a transaction dated Monday, November 18th. The shares were bought at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the completion of the transaction, the chief executive officer now directly owns 38,439,563 shares of the company’s stock, valued at approximately $1,927,359,688.82. This trade represents a 0.26 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 28.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Bruker

Hedge funds have recently bought and sold shares of the business. True Wealth Design LLC raised its holdings in shares of Bruker by 4,636.4% during the third quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock worth $36,000 after acquiring an additional 510 shares in the last quarter. Eagle Bay Advisors LLC grew its stake in Bruker by 2,324.1% in the fourth quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 674 shares in the last quarter. UMB Bank n.a. lifted its holdings in shares of Bruker by 115.3% during the 3rd quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after buying an additional 354 shares during the last quarter. GAMMA Investing LLC increased its holdings in Bruker by 81.0% in the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock worth $60,000 after buying an additional 388 shares during the last quarter. Finally, Values First Advisors Inc. bought a new stake in Bruker in the third quarter worth approximately $73,000. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.